4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells

[1]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2022, Neuro-oncology.

[2]  A. Raabe,et al.  Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification , 2022, Cancers.

[3]  J. Rajadas,et al.  Oral hymecromone decreases hyaluronan in human study participants , 2022, The Journal of clinical investigation.

[4]  M. Brito,et al.  Therapeutic Options in Neuro-Oncology , 2022, International journal of molecular sciences.

[5]  B. Bibak,et al.  Anticancer mechanisms of Berberine: a good choice for glioblastoma multiforme therapy. , 2022, Current medicinal chemistry.

[6]  P. Kesharwani,et al.  Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways. , 2022, Seminars in cancer biology.

[7]  F. Shan,et al.  Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression , 2021, Signal Transduction and Targeted Therapy.

[8]  S. Lompardía,et al.  Antitumor effect of 4MU on glioblastoma cells is mediated by senescence induction and CD44, RHAMM and p-ERK modulation , 2021, Cell death discovery.

[9]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. , 2021, Neuro-oncology.

[10]  L. Alaniz,et al.  Targeting the Tumor Extracellular Matrix by the Natural Molecule 4-Methylumbelliferone: A Complementary and Alternative Cancer Therapeutic Strategy , 2021, Frontiers in Oncology.

[11]  S. Lompardía,et al.  4-Methylumbelliferone induces antitumor effects independently of hyaluronan synthesis inhibition in human acute leukemia cell lines. , 2021, Life sciences.

[12]  S. Rimpelová,et al.  Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics , 2021, Biology.

[13]  C. Kosmas,et al.  AN OVERVIEW OF CURRENT RESULTS WITH THE VINCRISTINE-IRINOTECAN-TEMOZOLOMIDE COMBINATION WITH OR WITHOUT BEVACIZUMAB IN PEDIATRIC, ADOLESCENCE AND ADULT SOLID TUMORS. , 2021, Critical reviews in oncology/hematology.

[14]  Arunandan Kumar,et al.  Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[15]  M. Abdel-Daim,et al.  Natural bioactive molecules: An alternative approach to the treatment and control of glioblastoma multiforme. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  J. Matés,et al.  Antioxidant responses related to temozolomide resistance in glioblastoma , 2021, Neurochemistry International.

[17]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[18]  B. Bibak,et al.  Zerumbone, a ginger sesquiterpene, inhibits migration, invasion, and metastatic behavior of human malignant glioblastoma multiforme in vitro , 2021, BioFactors.

[19]  P. Guldberg,et al.  Screening of metabolic modulators identifies new strategies to target metabolic reprogramming in melanoma , 2021, Scientific Reports.

[20]  H. Date,et al.  4-Methylumbelliferone administration enhances radiosensitivity of human fibrosarcoma by intercellular communication , 2021, Scientific Reports.

[21]  Jichao Ma,et al.  Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy , 2020, Cell Death & Disease.

[22]  F. Ducray,et al.  Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH -Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort , 2021 .

[23]  S. Mousavi,et al.  The current state of potential therapeutic modalities for glioblastoma multiforme: a clinical review. , 2020, Current drug metabolism.

[24]  G. Song,et al.  Antiproliferative Effect of 4-Methylumbelliferone in Epithelial Ovarian Cancer Cells Is Mediated by Disruption of Intracellular Homeostasis and Regulation of PI3K/AKT and MAPK Signaling , 2020, Pharmaceutics.

[25]  S. Lompardía,et al.  4-Methylumbelliferone as a potent and selective anti-tumor drug on a glioblastoma model. , 2020, Glycobiology.

[26]  A. Gorji,et al.  Curcumin Loaded in Niosomal Nanoparticles Improved the Anti-tumor Effects of Free Curcumin on Glioblastoma Stem-like Cells: an In Vitro Study , 2020, Molecular Neurobiology.

[27]  A. Sahebkar,et al.  Zerumbone Promotes Cytotoxicity in Human Malignant Glioblastoma Cells through Reactive Oxygen Species (ROS) Generation , 2020, Oxidative medicine and cellular longevity.

[28]  R. Bureau,et al.  Drug repositioning: a brief overview , 2020, The Journal of pharmacy and pharmacology.

[29]  S. Mirza,et al.  Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments , 2020, Cancers.

[30]  D. Gomez,et al.  New drugs are not enough-drug repositioning in oncology: An update , 2020, International journal of oncology.

[31]  K. Terabe,et al.  Chondroprotective effects of 4-methylumbelliferone and hyaluronan synthase-2 overexpression involve changes in chondrocyte energy metabolism , 2019, The Journal of Biological Chemistry.

[32]  C. Ricciardelli,et al.  4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer , 2019, Cancers.

[33]  H. Sadeghnia,et al.  Auraptene-induced cytotoxicity mechanisms in human malignant glioblastoma (U87) cells: role of reactive oxygen species (ROS) , 2019, EXCLI journal.

[34]  S. Lompardía,et al.  Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines , 2019, Scientific Reports.

[35]  N. Karamanos,et al.  Tumor-suppressive functions of 4-MU on breast cancer cells of different ER status: Regulation of hyaluronan/HAS2/CD44 and specific matrix effectors. , 2019, Matrix biology : journal of the International Society for Matrix Biology.

[36]  M. Grandoch,et al.  4-Methylumbelliferyl glucuronide contributes to hyaluronan synthesis inhibition , 2019, The Journal of Biological Chemistry.

[37]  Y. Hosokawa,et al.  Regulation of radiosensitivity by 4-methylumbelliferone via the suppression of interleukin-1 in fibrosarcoma cells. , 2019, Oncology letters.

[38]  Atique U. Ahmed,et al.  Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation. , 2019, JCO clinical cancer informatics.

[39]  A. Mansouri,et al.  MGMT Testing in Glioblastomas: Pitfalls and Opportunities , 2019, American journal of clinical oncology.

[40]  K. Aldape,et al.  MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. , 2018, Neuro-oncology.

[41]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[42]  H. Shimoda,et al.  4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil , 2018, AntiCancer Research.

[43]  W. Wick,et al.  Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas , 2018, Cancer.

[44]  寛 大岩.  早期関節リウマチ：brief overview , 2018 .

[45]  J. Hung,et al.  Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase , 2017, Redox biology.

[46]  S. Lompardía,et al.  4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines , 2017, Investigational New Drugs.

[47]  Mark Huang,et al.  Update on Brain Tumors: New Developments in Neuro‐oncologic Diagnosis and Treatment, and Impact on Rehabilitation Strategies , 2016, PM & R : the journal of injury, function, and rehabilitation.

[48]  Hao Ban,et al.  Inhibition of hyaluronic acid formation sensitizes chronic myelogenous leukemia to treatment with doxorubicin. , 2016, Glycobiology.

[49]  S. Lompardía,et al.  Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. , 2016, Glycobiology.

[50]  Trevor Coward,et al.  An In-Vitro Study , 2016 .

[51]  Hao Ban,et al.  Hyaluronic Acid Inhibitor 4-Methylumbelliferone Activates the Intrinsic Apoptosis Pathway in K562 Chronic Myelogenous Leukemia Cells. , 2015, Anticancer research.

[52]  Ming-feng Yang,et al.  NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells. , 2015, Oncology letters.

[53]  J. Bollyky,et al.  4-Methylumbelliferone Treatment and Hyaluronan Inhibition as a Therapeutic Strategy in Inflammation, Autoimmunity, and Cancer , 2015, Front. Immunol..

[54]  M. Aghi,et al.  Bevacizumab for glioblastoma: current indications, surgical implications, and future directions. , 2014, Neurosurgical focus.

[55]  H. Poulsen,et al.  The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients , 2014, Cancer management and research.

[56]  Y. Sima,et al.  Antioxidative capacity in the fat body of Bombyx mori is increased following oral administration of 4-methylumbelliferone. , 2014, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[57]  S. Lompardía,et al.  Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy. , 2013, Glycobiology.

[58]  J. Bayo,et al.  Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. , 2012, Glycobiology.

[59]  N. Ishiguro,et al.  Inhibition of hyaluronan synthesis in breast cancer cells by 4‐methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo , 2012, International journal of cancer.

[60]  J. Sarkaria,et al.  Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain* , 2010, The Journal of Biological Chemistry.

[61]  V. Lokeshwar,et al.  Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. , 2010, Cancer research.

[62]  M. Tammi,et al.  4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. , 2009, Experimental cell research.

[63]  T. Kubota,et al.  The combined effects of multiple chemotherapeutic agents for malignant glioma cells , 2007, Journal of Neuro-Oncology.

[64]  I. Kakizaki,et al.  4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells , 2005, Cancer Chemotherapy and Pharmacology.

[65]  É. Álvarez,et al.  Correlation Between Decreased Apoptosis and Multidrug Resistance (MDR) in Murine Leukemic T Cell Lines , 2001, Leukemia & lymphoma.

[66]  K. Johnson.  An Update. , 1984, Journal of food protection.

[67]  Brian F. Blake,et al.  Pitfalls and Opportunities , 1978 .

[68]  J. Sneep,et al.  With a summary , 1945 .

[69]  G. Fraedrich,et al.  Juvenile recurrent respiratory papillomatosis: Still a mystery disease with difficult management , 2007, Head & neck.